How were Cepheid's earnings last quarter?

Cepheid (NASDAQ:CPHD) released its quarterly earnings data on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.19. The scientific and technical instruments company earned $146 million during the quarter, compared to the consensus estimate of $145.82 million. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.06) EPS.

What other stocks do shareholders of Cepheid own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cepheid investors own include Editas Medicine (EDIT) , General Electric (GE) , Gilead Sciences (GILD) , AK Steel (AKS) , Danaher (DHR) , Intel (INTC) , QUALCOMM (QCOM) , Alibaba Group (BABA) , Ford Motor (F) and FactSet Research Systems (FDS) .

NASDAQ:CPHD

Cepheid (CPHD) Stock Price, News & Analysis

→ Nerd Investor Reveals Secret To Make Money With A.I. (From InvestorPlace) (Ad)

Free CPHD Stock Alerts

Notice: Cepheid stock has been delisted and is no longer actively trading. Cepheid is now a division of Danaher Corporation (NYSE:DHR).

Today's Range: $52.95
▼
$52.95
50-Day Range: N/A
52-Week Range: $25.09
▼
$53.91

Volume: N/A
Average Volume: 1.25 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Cepheid alerts:

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Cepheid Stock (NASDAQ:CPHD)

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

CPHD Stock News Headlines

November 15, 2023 | forbes.com

In The Fight To End Tuberculosis, This Is The Moment For Progress

July 22, 2023 | bbc.com

Reducing the spread of hepatitis C

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

June 27, 2023 | it.tmcnet.com

SpotSee Forms Life Science Advisory Council with Global Industry Leaders

May 14, 2023 | thestreet.com

Cepheid (CPHD) Showing Signs Of Being Water-Logged And Getting Wetter

October 13, 2022 | businesswire.com

Global Biochips Market Research Report 2022: Market to Surpass $25+ Billion by 2026 - ResearchAndMarkets.com - Business Wire

October 7, 2022 | businesswire.com

The Worldwide Infectious Disease In Vitro Diagnostics Industry is Expected to Reach $56.6 Billion by 2030 - ResearchAndMarkets.com - Business Wire

October 7, 2022 | benzinga.com

Global Infectious Disease In Vitro Diagnostics Market Report (2022 to 2030) - High Demand for PoC Facilit - Benzinga

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

October 6, 2022 | globenewswire.com

Global COVID-19 Testing Industry - GlobeNewswire

September 30, 2022 | globenewswire.com

Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays - GlobeNewswire

September 30, 2022 | nasdaq.com

Key Reasons to Retain Danaher (DHR) Stock in Your Portfolio - Nasdaq

September 29, 2022 | finance.yahoo.com

Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays - Yahoo Finance

September 29, 2022 | streetinsider.com

Lucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays - StreetInsider.com

September 28, 2022 | streetinsider.com

SystemOne Wins Multi-Country, Multi-Device Subcontract through the Infectious Disease Detection and Surveillance Project - StreetInsider.com

September 20, 2022 | prnewswire.com

Global Oncology Molecular Diagnostics Market Report 2022: A $7.28 Billion Market by 2027 - Rise in Demand for Point-of-care Treatment - PR Newswire

September 16, 2022 | businesswire.com

Worldwide Tuberculosis Diagnosis and Treatment Industry to 2028 - by Diagnosis, Drugs, End-user and Region - ResearchAndMarkets.com - Business Wire

September 15, 2022 | nasdaq.com

Danaher (DHR) to Spin-Off Environmental Unit, Shares Pop - Nasdaq

September 14, 2022 | businesswire.com

Global Oncology Molecular Diagnostics Markets, 2022-2027 - Rising Number of R&D Activities & Technological Advancements in Diagnostic Testing - ResearchAndMarkets.com - Business Wire

September 2, 2022 | bizjournals.com

How monkeypox could help Karius underscore case for its broad pathogen test - San Francisco Business Times - The Business Journals

August 29, 2022 | globenewswire.com

With 6.1% CAGR, Global Tuberculosis Diagnostics Market Size Worth USD 3.13 Billion during Forecast [2022-2029] - GlobeNewswire

August 24, 2022 | globenewswire.com

With 4.1% CAGR, Canada Sexually Transmitted Disease Testing Market Size worth USD 310.5 Million in 2028 - Report by Fortune Business Insights - GlobeNewswire

August 17, 2022 | gurufocus.com

Weitz Analyst Corner: Danaher - GuruFocus.com

July 28, 2022 | businesswire.com

Global Covid Diagnostics Market (2022 to 2027) - Launch of Innovative Products Presents Opportunities - ResearchAndMarkets.com - Business Wire

July 23, 2022 | seekingalpha.com

Danaher Corporation's (DHR) CEO Rainer Blair on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

July 22, 2022 | prnewswire.com

Global COVID-19 Diagnostics Market Forecasts, 2022-2027: Time to Market and Preparedness Issues - PR Newswire

July 6, 2022 | globenewswire.com

Companies In The COVID-19 Rapid Test Kits Market Help Ease - GlobeNewswire

See More Headlines

Receive CPHD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cepheid and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/28/2016
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:CPHD
CUSIP: 15670R10
CIK: 1037760
Web: www.cepheid.com
Phone: +1-408-5414191
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

CPHD Stock Analysis - Frequently Asked Questions

How were Cepheid's earnings last quarter?: Cepheid (NASDAQ:CPHD) released its quarterly earnings data on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.19. The scientific and technical instruments company earned $146 million during the quarter, compared to the consensus estimate of $145.82 million. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.06) EPS.
What other stocks do shareholders of Cepheid own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cepheid investors own include Editas Medicine (EDIT), General Electric (GE), Gilead Sciences (GILD), AK Steel (AKS), Danaher (DHR), Intel (INTC), QUALCOMM (QCOM), Alibaba Group (BABA), Ford Motor (F) and FactSet Research Systems (FDS).

This page (NASDAQ:CPHD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cepheid (CPHD) Stock Price, News & Analysis

About Cepheid Stock (NASDAQ:CPHD)

CPHD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

CPHD Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info